Aspira Women's Health Inc. stock is down -19.85% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 54.17% of the previous 23 December’s closed higher than November.
Aspira Women's Health Inc. engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVAInherit tests to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of Gynecologic cancer.